A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Relapsed or Refractory B Cell Non Hodgkin Lymphoma
DRUG: B019
Dose-limiting toxicity (DLT), Measurement of DLT of B019 in all subjects, Approximately 2 years|MTD（Maximum tolerated dose）, Maximum tolerated dose, Approximately 2 years
The overall response rate (ORR), Tumor response will be evaluated according to the Lugano 2014 criteria., Approximately 2 years
The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.